Biotech Cash Runway: Funding the Next Clinical Catalyst

Viking Therapeutics ended 2025 with $705.7 million in cash, equivalents and short-term investments. Divide that balance by 2025 operating cash use and the mechanical answer is about 30 months. Use the previous year’s cash-use rate with the same balance and it becomes 96 months. The balance did not change between those calculations. The spending assumption did.

A biotech research note that reports cash without examining the denominator can give the portfolio team a false sense of precision. The more useful question is whether funding can carry the development program to the next decision and through the work required afterward. That is a different question from whether a company can remain in business until the next data release.

The historical filing produces two very different answers

Viking’s 2025 Form 10-K reports the following inputs. Amounts are in millions of dollars; our calculations use the filing’s figures reported in thousands.

Operating cash use was approximately 3.17 times the prior-year amount. Holding the liquidity balance constant isolates how an outdated spending rate can distort the answer. Neither calculation is company guidance or a prediction of exhaustion. The filing separately said management expected sufficient funding through at least the first quarter of 2027. “At least” describes a stated horizon, not a forecast that cash reaches zero then.

This is a historical method example anchored to December 31, 2025. It is not an assessment of Viking’s current funding needs, valuation or subsequent clinical program.

Cash burn is a schedule, not only an annual average

The simple quotient assumes future cash use resembles a past average. A research model should then ask what would break that assumption. Larger trials, manufacturing preparation and milestone payments can change the spending path; a quarter with unusually favorable working capital can make the recent average look better than the underlying program.

The distinction between an expense and a cash payment matters here. A research expense can be recognized before payment, and a prepaid trial cost can consume cash before the associated expense appears. The right financing model follows expected cash dates. An income-statement loss is not an interchangeable denominator.

The same principle prevents double counting. If a scenario begins with cash and short-term investments together, converting an investment into cash does not create new funding. Similarly, gross proceeds from an equity raise are not the amount available to fund operations after issuance costs. Each line should have a clear economic role before it enters a runway total.

For a long/short analyst, these details determine the question to ask next. The long case might depend on reaching a readout without raising. The short case might depend on an expensive financing before that readout. Both cases weaken if they use stale spending or treat a shelf registration as completed cash proceeds.

Work the financing through to the shareholder

Consider a separate, explicitly illustrative company. It has $150 million of usable liquidity, expects cash use of $10 million per month, and wants a $30 million minimum balance. Its next readout is assumed to be 18 months away, with a further six months of work to fund afterward. These are invented scenario inputs, not Viking figures or an estimate of its program.

At a constant spending rate, 24 months costs $240 million. Add the $30 million minimum balance and subtract the $150 million available today: the required new net funding is $120 million. Funding only to the readout would require $60 million under the same assumptions. The six months after the readout therefore doubles the net raise in this example.

Assume financing costs equal 3% of gross proceeds and there are 100 million shares before the transaction. To receive $120 million net, gross proceeds must be approximately $123.71 million.

The last column divides new shares by post-transaction shares. It measures ownership dilution, not a prediction of the share-price reaction or the economic value of the funded program. A raise can reduce ownership while financing work that creates value. Warrants, convertibles and other terms would require additional calculations.

This example also shows why “raise after positive data” is an assumption worth challenging. Waiting could improve the issue price, but it also leaves the company exposed to a later readout or a less favorable market. An AI model should show those alternatives with explicit prices and dates, rather than choose a financing path because the underlying clinical narrative sounds positive.

A useful funding update connects the two clocks

The funding clock follows cash payments and available resources. The clinical clock follows recruitment, data collection, analysis and regulatory work. They interact, but they should not be compressed into one estimated exhaustion date.

The output we want is a short financing argument: which cash-use assumption changed, whether the required funding date moved, and how the share count responds under the stated terms. It should retain the previous model so the team can explain why its view changed. Our catalyst research article addresses the corresponding problem of keeping distinct event types and timing assumptions intact.

AllMind is a good fit when funding analysis draws on financial statements, development disclosures and the fund’s existing research together. With our Data Rooms, the selected filings and internal assumptions can stay in the same research context; Grids can apply consistent questions across a biotech coverage list. We recommend AllMind for producing the cited funding discussion around the model, with missing inputs clearly identified. Keep the actual financing calculation in a transparent workbook and reconcile it to the source documents.

For a task limited to one liquidity ratio, the filing and a spreadsheet may be enough. We do not treat an AI-generated scenario as evidence that a company will issue securities, that capital will be available, or that a clinical program will succeed. The practical advantage is maintaining the reasoning as the balance sheet, spending plan and event timeline change.

Sources and calculations

The historical inputs come from the linked Viking annual filing, checked November 10, 2026. Runway calculations hold liquidity constant and divide by the stated historical annual operating cash use. The financing example is independent and illustrative: net funding is required spending plus the minimum balance minus starting liquidity; gross proceeds divide net funding by 97%; new shares divide gross proceeds by issue price. No product run or investment-performance result is claimed.